Botswana, once hailed as one of Africa’s most prosperous nations, is grappling with a healthcare crisis that highlights the stark realities of economic downturns stemming from diamond price collapses. Patients like Boitumelo Mosege, diagnosed with hyperthyroidism, are facing severe shortages of essential medications, forcing them to navigate a system that is failing to provide the universal healthcare promised by the government. The economic repercussions of a diamond market slump, compounded by rising unemployment and insufficient government response, are laying bare the fragility of Botswana’s healthcare framework.
The Human Cost of Medication Shortages
In late 2023, Boitumelo Mosege’s health began to deteriorate, culminating in a diagnosis of hyperthyroidism that forced her to abandon her role as a farmer near Molepolole, about 30 miles from Gaborone. Despite Botswana’s public healthcare system being designed to offer free services, Mosege has found herself reliant on the erratic support of her children and her mother’s modest pension to afford her monthly medication, which costs approximately 2,000 pula (£112). “It’s been three months since I could buy my medicine,” she lamented. “I felt like I had lost my life right there. I felt suicidal
